VIE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Viela Bio's Total Stockholders Equity for the quarter that ended in Dec. 2020 was $375.83 Mil. Viela Bio's Total Assets for the quarter that ended in Dec. 2020 was $423.26 Mil. Therefore, Viela Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2020 was 0.89.
The historical rank and industry rank for Viela Bio's Equity-to-Asset or its related term are showing as below:
During the past 3 years, the highest Equity to Asset Ratio of Viela Bio was 0.92. The lowest was 0.89. And the median was 0.91.
The historical data trend for Viela Bio's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viela Bio Annual Data | |||||||
Trend | Dec18 | Dec19 | Dec20 | ||||
Equity-to-Asset | -1.35 | 0.92 | 0.89 |
Viela Bio Quarterly Data | ||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.92 | 0.92 | 0.91 | 0.95 | 0.89 |
For the Biotechnology subindustry, Viela Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viela Bio's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Viela Bio's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Viela Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as
Equity to Asset (A: Dec. 2020 ) | = | Total Stockholders Equity | / | Total Assets |
= | 375.828 | / | 423.257 | |
= | 0.89 |
Viela Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2020 is calculated as
Equity to Asset (Q: Dec. 2020 ) | = | Total Stockholders Equity | / | Total Assets |
= | 375.828 | / | 423.257 | |
= | 0.89 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viela Bio (NAS:VIE) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Viela Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Chris Nolet | director | C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Rachelle Suzanne Jacques | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Edward Hu | director | 10975 TORREY PINES ROAD, LA JOLLA CA 92037 |
Boyu Capital General Partner Iii, L.p. | 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Boyu Capital General Partner Iii, Ltd. | 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Boyu Capital Group Holdings Ltd. | 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Xyxy Holdings Ltd. | 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Boyu Capital Investment Management Ltd | 10 percent owner | SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Boundless Meadow Ltd | 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Xiaomeng Tong | director, 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Yanling Cao | director, 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Boyu Capital Fund Iii, L.p. | 10 percent owner | C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104 |
Boyu Capital Opportunities Master Fund | 10 percent owner | CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008 |
Zhengbin Yao | director, officer: Chief Executive Officer | 10301 STELLA LINK ROAD, HOUSTON TX 77025 |
William Ragatz | officer: VP, Head of Commercial | C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878 |
From GuruFocus
By Marketwired Marketwired • 08-05-2020
By Marketwired Marketwired • 06-12-2020
By Marketwired Marketwired • 11-14-2019
By Marketwired Marketwired • 02-19-2021
By Marketwired Marketwired • 05-26-2020
By GlobeNewswire GlobeNewswire • 06-11-2020
By Marketwired Marketwired • 03-18-2020
By Marketwired Marketwired • 05-06-2020
By PRNewswire PRNewswire • 02-13-2021
By PRNewswire PRNewswire • 02-01-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.